title: Efficacy of DMSA Therapy in a Sample of Arab Children with Autistic Spectrum Disorder.
abstract: OBJECTIVE
  the aim of this study was to provide evidence that DMSA detoxification treatments cause a reduction of the heavy metal burden in the autistic, and that this reduction lessens neurological symptoms associated with ASD (Autistic Spectrum Disorder).
  
  
  METHODS
  The participants were 44 children, age 3 to 9 years of age, with Autistic Spectrum Disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders 4t Edition, (DMS-IV). The severity of the autistics symptomatologiy had been measured by the Childhood Autism Rating Scale (SCARS). We collected urine samples before and after the DMSA challenge test, comparing urine metal output. We also compared the results of the DMSA detoxification(=the urine challenge test) with behavioral effects, typical for ASD.
  
  
  RESULTS
  The DMSA challenge test increased the urine metal output for a number of potentially toxic metals. Statistically significant difference were noted between the baseline urine and DMSA challenge test regarding the level of cadmium, mercury, and lead (P=0.006, P=0.049, and P=0.008 respectively). We also noted that behavioral effects, typical for ASD (autism spectrum disorders) were reduced with this method of detoxification. A comparison between CARS Subscales and Total Score before and after a 6-month chelation program showed greatest improvements for Verbal and nonverbal communication (P <0.001), Taste, Smell and Touch (P 0.001) and Relating to People (P 0.005). Other improvements were noted for Adaptation to Change and Improvement.
  
  
  CONCLUSIONS
  DMSA chelation increased the urinary output of toxic and neurotoxic metals. Our data supports evidence that detoxification treatment with oral DMSA has beneficial effect on ASD patients.
authors: Lecturer, researcher and advisor, International Board of Clinical Metal Toxicology & German Medical Association of Clinical Metal Toxicology, Hersbruck, Germany.
authors: Eleonor
authors: E
authors: Blaucok-Busch
authors: Omnia R
authors: OR
authors: Amin
authors: Hani H
authors: HH
authors: Dessoki
authors: Thanaa
authors: T
authors: Rabah
keywords: adipokine; children; cytokine; obesity
references: BMC Clin Pharmacol. 2009 Oct 23;9:16
references: 19852789
references: J Child Neurol. 2007 Nov;22(11):1308-11
references: 18006963
references: Clin Toxicol (Phila). 2007 Jun-Aug;45(5):476-81
references: 17503250
references: J Altern Complement Med. 2004 Dec;10(6):1033-9
references: 15673999
references: Pediatr Int. 2011 Apr;53(2):147-53
references: 20626635
references: J Pharmacol Exp Ther. 1993 Nov;267(2):791-800
references: 8246154
references: BMC Clin Pharmacol. 2009 Oct 23;9:17
references: 19852790
references: Curr Med Chem. 2009;16(2):157-70
references: 19149568
references: J Clin Psychiatry. 2005;66 Suppl 10:3-8
references: 16401144
references: J Neurol Sci. 2009 May 15;280(1-2):101-8
references: 18817931
references: J Autism Dev Disord. 1999 Dec;29(6):439-84
references: 10638459
references: J Dev Behav Pediatr. 2002 Feb;23(1 Suppl):S13-22
references: 11875286
references: Biol Trace Elem Res. 2010 Jun;135(1-3):10-5
references: 19688188
references: Biochem Pharmacol. 1984 Apr 1;33(7):1093-8
references: 6712719
references: Fundam Appl Toxicol. 1985 Oct;5(5):816-31
references: 4065458
references: Med Hypotheses. 2001 Apr;56(4):462-71
references: 11339848
references: J Autism Dev Disord. 1998 Feb;28(1):77-81
references: 9546305
references: Maedica (Bucur). 2012 Jan;7(1):38-48
references: 23118818
references: Neuro Endocrinol Lett. 2002 Aug;23(4):303-8
references: 12195231
references: J Toxicol. 2009;2009:532640
references: 20107587
references: Neurosciences (Riyadh). 2005 Jul;10(3):213-8
references: 22473261